Glucan-based ultra-small magnetic nanoparticles, and preparation method and application thereof

Through ultra-small magnetic nanoparticles based on dextran, the kidney clearance pathway is used to accelerate the excretion of nanoparticles and activate and release metal ions in an acidic environment, solving the toxicity of inorganic nanoparticles retention and degradation products to the organs, and improving the Sensitivity and accuracy of magnetic resonance imaging.

CN118924922APending Publication Date: 2024-11-12HUNAN UNIV +1
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202411005373.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-25
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The biotoxicity risk caused by the retention of existing inorganic nanoparticles in the body, and their degradation products may cause serious damage to the organs, making it difficult to effectively accelerate their removal and degradation in the body.

Method used

Using ultra-small magnetic nanoparticles based on dextran, crosslinked dextran is used as the core, loading amorphous magnetic metal oxides as the shell, and accelerating the excretion of nanoparticles through the kidney clearance pathway, while at the same time in acidity Release metal ions are activated in the environment to improve magnetic resonance imaging.

Benefits of technology

The rapid clearance of nanoparticles through the kidneys is achieved, the risk of biotoxicity is reduced, and the sensitivity and accuracy of magnetic resonance imaging is improved through targeted modification and acid activation functions. It is suitable for imaging of tumors, inflammation and other diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118924922A_ABST
    Figure CN118924922A_ABST
Patent Text Reader

Abstract

The invention discloses a dextran-based ultra-small magnetic nanoparticle as well as a preparation method and application thereof. The nanoparticle takes surface carboxylated cross-linked dextran (Dex-COOH) as a core and takes surface loaded amorphous magnetic metal oxide as a shell layer; the metal in the amorphous magnetic metal oxide comprises one or more of Fe, Mn, Co, Ni, Cu, Zn, Gd, Dy and Ho. According to the invention, the surface carboxylated cross-linked dextran is taken as a core, the ultra-small magnetic nanoparticles with various metal shell layers are conveniently and quickly synthesized, and due to the ultra-small hydration dynamic size, the synthesized nanoparticles can be metabolized through kidneys, so that the potential toxicity of the nanoparticles applied to living bodies is greatly reduced. The nanoparticles are prepared through simple room-temperature stirring, the preparation process is short, operation is easy, and the cost is low.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of nano material preparation, and specifically relates to ultra-small magnetic nanoparticles based on dextran, a preparation method and application thereof. Background Art

[0002] Inorganic nanoparticles have excellent optical, electrical, magnetic and catalytic properties and have broad application prospects in bioimaging, drug delivery, tissue repair, tumor diagnosis and treatment. For example, quantum dots (QDs) have excellent photostability, tunable fluorescence emission and large Stokes shift, showing great potential in labeling targets. Iron oxide nanoparticles (IONPs) can be used as magnetic resonance imaging (MRI) contrast agents and thermal therapeutic agents due to their great magnetic properties. Gold nanoparticles (AuNPs) have been widely studied in CT imaging, biosensing and photothermal therapy due to their high X-ray absorption efficiency, size- and shape-related optical properties.

[0003] Despite the promising application prospects of nanoparticles, their application from the laboratory to the clinic is largely hindered by the potential biotoxicity risk caused by the retention of inorganic nanoparticles in the body. It has been reported that nanoparticles larger than 10 nm are easily captured by the reticuloendothelial system (RES, such as liver, spleen, and bone marrow). In addition, their surface charge usually leads to protein absorption, and the resulting larger nanoparticles are taken up by macrophages and accumulate in major organs such as liver, spleen, and lungs, thereby prolonging the excretion time and increasing safety risks. Previous toxicity studies on phospholipid micelle-encapsulated CdSe / CDS / ZnS quantum dots have shown that most intravenously injected quantum dots remain in the RES even 90 days after injection. Ideally, the injected nanomaterials must be cleared from the body as soon as possible after the mission is completed, otherwise the nanomaterials and their degradation products, such as metal ions, may cause serious safety issues (such as nephrogenic systemic fibrosis and central nervous system diseases). Therefore, how to accelerate the metabolism of nanomaterials in the body and minimize their nonspecific accumulation has always been a major challenge.

[0004] At present, the known excretion pathways of nanoparticles mainly include the liver-bile pathway and the kidney-urine pathway. Based on the above pathways, two feasible solutions have been proposed to promote the metabolism of nanoparticles. The first is to improve the biodegradability of nanomaterials, allowing them to be degraded and excreted as quickly as possible after being captured by the liver or other organs. Many biodegradable nanoparticles have been developed for in vivo biomedical applications, including inorganic nanoparticles (such as silica, iron oxide, manganese dioxide), organic nanoparticles (such as polymer nanoparticles and liposomes), and inorganic / organic hybrid nanoparticles (such as mesoporous silica-gelatin hybrid nanoparticles). Compared with the other two corresponding nanoparticles, inorganic nanoparticles generally have higher chemical stability and relatively slower degradation rate, which is more likely to lead to long-term retention in the body, resulting in complex nano-bio interactions. In addition, since the physical and chemical properties of inorganic nanomaterials are mostly size-related, their properties may be significantly changed by degradation and become inconsistent with those of the initial nanomaterials, resulting in poor or even inaccurate diagnostic results. In addition, the degradation products of some inorganic nanomaterials contain heavy metal ions or intermediates, which may cause serious toxicity and damage to organs during metabolism. From these aspects, improving the biodegradability of inorganic nanoparticles may not be a perfect solution.

[0005] The second way to accelerate the excretion of nanoparticles from the body is to improve their renal clearance efficiency. In order to be excreted through the urinary system, nanoparticles must pass through three layers of renal filtration barriers, namely the endothelium, the reticular glomerular basement membrane, and the epithelial layer. Nanoparticles with a hydrodynamic size of less than 8nm can be effectively cleared from the body through the kidneys, depending on the different restrictions of the pore or filtration slit structure. Therefore, ultrasmall sized nanoparticles can enable the nanoparticles to be eliminated by the kidneys and accelerate their clearance from the body. So far, many renal-clearable nanoplatforms have been developed at an astonishing rate, such as ultrasmall IONPs, AuNPs, QDs, and carbon dots. Unlike biodegradable nanoparticles, renal-clearable nanoparticles are usually excreted in their original state. Summary of the invention

[0006] In view of the deficiencies in the prior art, the purpose of the present invention is to provide an ultra-small magnetic nanoparticle based on dextran, a preparation method and its application. The prepared nanoparticles have an ultra-small hydrodynamic size and can be cleared by the kidneys. The surface of the nanoparticles can be modified with targets to serve as targeted nuclear magnetic resonance imaging contrast agents, and have different nuclear magnetic resonance imaging effects depending on the different loaded metal complexes.

[0007] In order to achieve the above object, the present invention provides the following technical solutions:

[0008] A dextran-based ultra-small magnetic nanoparticle, the nanoparticle has a surface carboxylated cross-linked dextran (Dex-COOH) as a core and an amorphous magnetic metal oxide loaded on the surface as a shell;

[0009] The metal in the amorphous magnetic metal oxide includes one or more of Fe, Mn, Co, Ni, Cu, Zn, Gd, Dy, and Ho.

[0010] The dextran-based ultrasmall magnetic nanoparticles are represented as Dex-Fe, Dex-Mn, Dex-Co, Dex-Ni, Dex-Cu, Dex-Zn, Dex-Gd, Dex-Dy, and Dex-Ho.

[0011] In a preferred embodiment, the surface of the nanoparticle is further modified with a target.

[0012] In a preferred embodiment, the surface carboxylated cross-linked dextran has a uniform spherical structure, and its particle size is 1 to 50 nm.

[0013] In a preferred embodiment, the dextran-based ultrasmall magnetic nanoparticles have a uniform spherical structure, and the particle size thereof is 1 to 100 nm.

[0014] The present invention also provides a method for preparing the ultrasmall magnetic nanoparticles based on dextran, comprising the following steps:

[0015] (1) Synthesis of Dex-COOH: Add dextran, a cross-linking agent, a base, and water to a first reaction vessel and stir to react; add an amination agent, continue to stir to react, and add ethanol to precipitate the product; take the precipitate and disperse it in water, add a carboxylation agent, stir to react again, and wash the crude product to obtain Dex-COOH;

[0016] (2) Synthesis of ultrasmall magnetic nanoparticles based on dextran: Dex-COOH obtained in step (1), a metal inorganic salt, and water are added to a second reaction container, and stirred to react. Then, a base is added, and the stirring reaction is continued. The intermediate product is washed to obtain ultrasmall magnetic nanoparticles based on dextran;

[0017] (3) Modifying the target: Add the dextran-based ultrasmall magnetic nanoparticles obtained in step (2), functionalized polyethylene glycol, a coupling agent, and water to a third reaction container, stir to react, concentrate the resulting mixed solution, add the target, shake for a set time, and then wash the resulting product to obtain target-modified ultrasmall magnetic nanoparticles.

[0018] Furthermore, in the step (1), the cross-linking agent is one or more of epichlorohydrin and epichlorohydrin;

[0019] The base is one or more of NaOH, NH3·H2O, and NaCO3;

[0020] The amination agent is one or more of ammonia water and ethylenediamine;

[0021] The carboxylating agent is one or more of succinic anhydride and glutaric anhydride.

[0022] Furthermore, in the step (1), the added amounts of the raw materials are: dextran 0.1-1 mmol, cross-linking agent 10-100 mmol, base 50-200 mmol; amination agent 0.1-1 mol, ethanol 30-100 mL; the molar ratio of carboxylation agent to dextran is (1-50):1.

[0023] Furthermore, in step (2), the metal inorganic salt is one or more of metal chlorides, sulfates, and nitrates;

[0024] The base is one or more of NaOH, NH3·H2O, and NaCO3.

[0025] Furthermore, in the step (2), the added amounts of the raw materials are: Dex-COOH 8-24 mg, metal inorganic salt 0.1-1 mmol, and base 0.1-1 mmol.

[0026] Furthermore, in step (3), the functionalized polyethylene glycol is one or more of NH2-PEG-MAL, NH2-PEG-COOH, and NH2-PEG;

[0027] The coupling agent is one or more of 1-ethyl-(3-dimethylaminopropyl)carbodiimide (EDC) and (N-hydroxysulfosuccinimide) (Suflo-NHS);

[0028] Furthermore, in step (3), the added amounts of the raw materials are: 10-50 mg of dextran-based ultrasmall magnetic nanoparticles, 5-50 mg of functionalized polyethylene glycol, 10-100 mg of coupling agent, and 1-10 mg of target.

[0029] The present invention provides the application of the dextran-based ultrasmall magnetic nanoparticles as a magnetic resonance imaging contrast agent.

[0030] The present invention also provides application of the target-modified ultrasmall magnetic nanoparticles as magnetic resonance imaging contrast agents.

[0031] The contrast agent can be cleared by the kidneys, has high biosafety, and is used for imaging of various diseases, such as vascular imaging, tumor imaging, inflammation imaging, etc.

[0032] Furthermore, the metal in the amorphous magnetic metal oxide is Mn, and the obtained dextran-based ultrasmall magnetic nanoparticles Dex-Mn are used as magnetic resonance imaging contrast agents. Dex-Mn is activated in an acidic environment to release Mn ions, which can significantly improve the T1-weighted magnetic resonance imaging contrast of the disease site and is used for tumor pH imaging, inflammation imaging, and atherosclerosis imaging.

[0033] Furthermore, the dextran-based ultrasmall magnetic nanoparticles Dex-Mn are combined with the target to obtain target-modified Dex-Mn, which is used as a targeted and activated magnetic resonance imaging contrast agent for sensitive and precise imaging of various diseases.

[0034] Compared with the existing technology, the present invention has the following beneficial effects:

[0035] (1) The present invention provides a method for preparing ultrasmall magnetic nanoparticles based on dextran, which uses surface carboxylated cross-linked dextran as the core to conveniently and quickly synthesize ultrasmall magnetic nanoparticles with various metal shells. In addition, due to the ultrasmall hydration dynamic size, the synthesized nanoparticles can be metabolized by the kidneys, greatly reducing the potential toxicity of these nanoparticles when used in vivo.

[0036] (2) The present invention prepares nanoparticles by simple room temperature stirring, which has a short preparation process, simple operation and low cost.

[0037] (3) The present invention provides ultra-small magnetic nanoparticles Dex-Mn with Mn loaded on the surface. The nanoparticles can be activated to release Mn ions in an acidic environment, which can significantly improve the T1-weighted magnetic resonance imaging contrast of the diseased site, solve the problem of low sensitivity of magnetic resonance imaging, and can be used for tumor pH imaging, inflammation imaging, and atherosclerosis imaging.

[0038] (4) The present invention designs a targeted and activated magnetic resonance imaging contrast agent by modifying the target on the surface of Dex-Mn, which can significantly amplify the magnetic resonance imaging effect on the target substrate, further improve the sensitivity of magnetic resonance imaging, and be used for sensitive and accurate imaging of various diseases. BRIEF DESCRIPTION OF THE DRAWINGS

[0039] Figure 1 Diagram of the preparation process of ultrasmall magnetic nanoparticles based on dextran;

[0040] Figure 2 TEM image of Dex-Mn nanoparticles;

[0041] Figure 3 TEM image of Dex-Fe nanoparticles;

[0042] Figure 4 DLS patterns of Dex-Mn and Dex-Fe nanoparticles;

[0043] Figure 5 Dex-Mn nanoparticle acid-responsive magnetic resonance imaging signals;

[0044] Figure 6 Magnetic resonance imaging signal of Dex-Fe nanoparticles;

[0045] Figure 7 Dex-Mn nanoparticles for magnetic resonance imaging of subcutaneous tumors;

[0046] Figure 8 Dex-Mn nanoparticles for inflammation-targeted magnetic resonance imaging. DETAILED DESCRIPTION

[0047] The specific implementation of the present invention is further described below by examples and drawings, but the specific implementation of the present invention is not limited to the following examples.

[0048] Example 1

[0049] The preparation process of ultrasmall magnetic nanoparticles based on dextran is as follows Figure 1 , including the following steps:

[0050] (1) Synthesis of surface carboxylated cross-linked dextran Dex-COOH: 1.8 g of dextran, 6.939 g of epichlorohydrin, 3 g of sodium hydroxide, and 24 mL of ultrapure water were added to a flask. After stirring at room temperature for 6 h, 22.8 g of ethylenediamine was added. After continuing to stir for 24 h, excess ethanol was added for precipitation and washing. The precipitate was dispersed in ultrapure water, 200 mg of succinic anhydride was added, and after stirring at room temperature for 24 h, ultrafiltration was performed to obtain the ultrasmall surface carboxylated cross-linked dextran Dex-COOH, which was freeze-dried for storage.

[0051] (2) Synthesis of ultrasmall magnetic nanoparticles based on dextran: 8 mg Dex-COOH, 1 mg metal inorganic salt (including Fe, Mn, Co, Ni, Cu, Zn, Gd, Dy, Ho), and 5 mL ultrapure water were added to a flask and stirred for a while. After adding 100 μL 1M NaOH solution and stirring at room temperature for 1 hour, ultrafiltration and washing were performed to obtain the ultrasmall magnetic nanoparticles Dex-Fe, Dex-Mn, Dex-Co, Dex-Ni, Dex-Cu, Dex-Zn, Dex-Gd, Dex-Dy, and Dex-Ho.

[0052] Figure 2 This is a transmission electron microscope (TEM) image of Dex-Mn. As shown in the figure, Dex-Mn presents a uniform spherical structure with a particle size of approximately 5 nm.

[0053] Figure 3This is a transmission electron microscope (TEM) image of Dex-Fe. As shown in the figure, Dex-Fe presents a uniform spherical structure with a particle size of approximately 5 nm.

[0054] Figure 4 This is a dynamic light scattering (DLS) graph. As shown in the figure, the hydrated particle size of Dex-COOH is about 5 nm, and the hydrated particle size of Dex-Fe and Dex-Mn is about 7 nm.

[0055] (3) Target modification: 20 mg Dex-Mn, 5 mg NH2-PEG-MAL, 10 mg EDC, 10 mg Suflo-NHS, and 10 ml ultrapure water were added to a flask, stirred for 4 h, ultrafiltered 3 times to 1 ml, and 5 mg of the neutrophil targeting peptide NEBP or the control peptide Con was added and shaken overnight. The mixture was ultrafiltered and washed to obtain target-modified ultrasmall magnetic nanoparticles Dex-Mn-NEBP or Dex-Mn-Con.

[0056] Example 2

[0057] Magnetic resonance imaging signal test based on Dex-Mn nanoparticles:

[0058] The Dex-Mn nanoparticles obtained in Example 1 were prepared into aqueous solutions containing the same Mn concentration and different HEPES buffers (pH = 7.4-6.4). After incubation for 2 h, the T1-weighted relaxation time was measured using a Bruker Minispec analyzer (60 MHz). The results are shown in Table 1. Figure 5 As shown in Figure 2, as the pH decreases from 7.4 to 6.4, the 1 / T1 of Dex-Mn gradually increases. Therefore, Dex-Mn nanoparticles have an acid-responsive enhanced T1 magnetic resonance imaging effect, because the release of manganese ions by Dex-Mn nanoparticles under the influence of acid accelerates the T1 relaxation of surrounding water protons, thereby enhancing the T1 imaging signal.

[0059] Example 3

[0060] Magnetic resonance imaging signal test based on Dex-Fe nanoparticles:

[0061] The Dex-Fe nanoparticles obtained in Example 1 were prepared into aqueous solutions containing different Fe concentration gradients and different HEPES buffers (pH = 7.4-6.4). After incubation for 2 h, the T1-weighted relaxation time was measured using a Bruker Minispec analyzer (60 MHz). The results are shown in Table 1. Figure 6 As shown in the figure, as the Fe concentration increases, the 1 / T1 of Dex-Fe gradually increases. As the pH decreases, the 1 / T1 of Dex-Fe remains unchanged. Therefore, Dex-Fe does not have the acid response enhanced T1 magnetic resonance imaging effect.

[0062] Example 4

[0063] Dex-Mn for MRI of subcutaneous tumors:

[0064] All animal experiments were conducted in compliance with relevant laws and approved by the Institutional Animal Care and Use Committee of Hunan University. The Dex-Mn nanoparticles obtained in Example 1 were used; tumor-bearing mice (Balb / c, 4T1) were anesthetized with liquid anesthesia (5% chloral hydrate), and Dex-Mn (Mn, 5 mg / kg) was injected through the tail vein, and T1-weighted magnetic resonance imaging images were collected before and after the injection. Figure 7 As shown in the figure, the tumor area becomes significantly brighter after the injection of Dex-Mn compared with the magnetic resonance image before the injection, indicating that Dex-Mn can quickly accumulate and respond in the tumor site. At the same time, the signal at the bladder position also becomes brighter with the increase of injection time, indicating that Dex-Mn can be quickly metabolized to the bladder through the kidneys, that is, it can be quickly cleared from the body, proving that it has high biological safety.

[0065] Example 5

[0066] Dex-Mn for targeted imaging of subcutaneous inflammation:

[0067] All animal experiments complied with relevant laws and were approved by the Institutional Animal Care and Use Committee of Hunan University. C57BL / 6j mice were used, and 10 μg of LPS was injected into the legs of each mouse to induce leg inflammation. The mice were used for MRI 24 hours after LPS injection. Dex-Mn-Con and Dex-Mn-NEBP nanoparticles obtained in Example 1 were injected into the mice through the tail vein with Dex-Mn-Con or Dex-Mn-NEBP (Mn, 5 mg / kg), and T1-weighted MRI probes were collected before and after the injection of the two nanoparticles. Figure 8 As shown, the signals at the inflammatory sites in the legs of mice injected with Dex-Mn-NEBP nanoparticles were more obvious, indicating that Dex-Mn-NEBP nanoparticles have good imaging effects of targeting and amplifying inflammation.

[0068] The ultra-small magnetic nanoparticles of the present invention have an ultra-small hydration power size and can be cleared by the kidneys, greatly reducing the potential biological toxicity of the nanoparticles in the body. The ultra-small magnetic nanoparticles of the present invention have different nuclear magnetic imaging effects according to the different metal complexes loaded. Among them, the Dex-Mn nanoparticles loaded with the Mn complex shell have a sensitive acid-activated nuclear magnetic imaging effect and can be used for imaging diseases such as tumors and inflammation. At the same time, the surface of the ultra-small magnetic nanoparticles of the present invention is easy to modify, and the acid-activated Dex-Mn is combined with the target to be used as a target-activated magnetic resonance imaging contrast agent, which can be used for rapid and sensitive imaging of markers such as tumors, inflammation, and atherosclerosis.

[0069] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.

Claims

1. An ultra-small magnetic nanoparticle based on dextran, characterized in that: The nanoparticles have surface carboxylated cross-linked dextran (Dex-COOH) as the core and surface-loaded amorphous magnetic metal oxide as the shell. The metal in the amorphous magnetic metal oxide includes one or more of Fe, Mn, Co, Ni, Cu, Zn, Gd, Dy, and Ho.

2. The ultrasmall magnetic nanoparticles based on dextran according to claim 1, characterized in that: The surface of the nanoparticle is also modified with a target.

3. The ultrasmall magnetic nanoparticles based on dextran according to claim 1 or 2, characterized in that: The surface carboxylated cross-linked dextran has a uniform spherical structure and a particle size of 1 to 50 nm.

4. The ultrasmall magnetic nanoparticles based on dextran according to claim 1 or 2, characterized in that: The dextran-based ultra-small magnetic nanoparticles have a uniform spherical structure and a particle size of 1 to 100 nm.

5. The method for preparing ultrasmall magnetic nanoparticles based on dextran according to any one of claims 1 to 4, characterized in that: The following steps are involved: (1) Synthesis of Dex-COOH: Add dextran, a cross-linking agent, a base, and water to a first reaction vessel and stir to react; add an amination agent, continue to stir to react, and add ethanol to precipitate the product; take the precipitate and disperse it in water, add a carboxylation agent, stir to react again, and wash the crude product to obtain Dex-COOH; (2) Synthesis of ultrasmall magnetic nanoparticles based on dextran: Dex-COOH obtained in step (1), a metal inorganic salt, and water are added to a second reaction container, and stirred to react. Then, a base is added, and the stirring reaction is continued. The intermediate product is washed to obtain ultrasmall magnetic nanoparticles based on dextran; (3) Modifying the target: Add the dextran-based ultrasmall magnetic nanoparticles obtained in step (2), functionalized polyethylene glycol, a coupling agent, and water to a third reaction container, stir to react, concentrate the resulting mixed solution, add the target, shake for a set time, and then wash the resulting product to obtain target-modified ultrasmall magnetic nanoparticles.

6. The method for preparing ultrasmall magnetic nanoparticles based on dextran according to claim 5, characterized in that: In the step (1), the cross-linking agent is one or more of epichlorohydrin and epichlorohydrin; The base is one or more of NaOH, NH3·H2O, and NaCO3; The amination agent is one or more of ammonia water and ethylenediamine; The carboxylating agent is one or more of succinic anhydride and glutaric anhydride; In the step (1), the added amounts of the raw materials are: 0.1-1 mmol of dextran, 10-100 mmol of cross-linking agent, 50-200 mmol of base; 0.1-1 mol of amination agent, 30-100 mL of ethanol; and the molar ratio of carboxylation agent to dextran is (1-50):

1.

7. The method for preparing ultrasmall magnetic nanoparticles based on dextran according to claim 5, characterized in that: In the step (2), the metal inorganic salt is one or more of metal chloride, sulfate, and nitrate; The base is one or more of NaOH, NH3·H2O, and NaCO3; In the step (2), the added amounts of the raw materials are: Dex-COOH 8-24 mg, metal inorganic salt 0.1-1 mmol, and base 0.1-1 mmol.

8. The method for preparing ultrasmall magnetic nanoparticles based on dextran according to claim 5, characterized in that: In the step (3), the functionalized polyethylene glycol is one or more of NH2-PEG-MAL, NH2-PEG-COOH, and NH2-PEG; The coupling agent is one or more of 1-ethyl-(3-dimethylaminopropyl)carbodiimide and (N-hydroxysulfosuccinimide); In the step (3), the added amounts of the raw materials are: 10-50 mg of dextran-based ultrasmall magnetic nanoparticles, 5-50 mg of functionalized polyethylene glycol, 10-100 mg of coupling agent, and 1-10 mg of target.

9. Use of the dextran-based ultrasmall magnetic nanoparticles according to any one of claims 1 to 4 as a magnetic resonance imaging contrast agent, wherein the contrast agent can be cleared by the kidney.

10. According to claim 1, the metal in the amorphous magnetic metal oxide is Mn, and the prepared Dex-Mn is used as a magnetic resonance imaging contrast agent for tumor pH imaging, inflammation imaging and atherosclerosis imaging.

Citation Information

Patent Citations

  • Production of soluble polysaccharide-based magnetic composite nano-grain

    CN101029138A

  • Aptamer target-based superparamagnetic iron oxide nanocomposite magnatic resonance imaging contrast agent

    CN102526770A

  • Inflammation targeting and microenvironment responsive nano system and preparation method and application thereof

    CN111514316A

  • Nanostructures for dispensing by urea through kits without by injected into a biological body by photophagases and

    CN118055781A